B7-2 / CD86 Molecule Synonym Name
B7-2 / CD86 Protein Products
|Cat No||Species||Product Description|
|CD6-C5254||Cynomolgus||Cynomolgus B7-2 / CD86 Protein, Fc Tag|
|CD6-C52H5||Cynomolgus||Cynomolgus B7-2 / CD86 Protein (HPLC-verified)|
|CD6-H5223||Human||Human B7-2 / CD86 Protein|
|CD6-H5257||Human||Human B7-2 / CD86 Protein, Fc Tag|
|CD6-H82E2||Human||Biotinylated Human B7-2 / CD86 Protein, Avi Tag (Avitag?)|
|CD6-H82F5||Human||Biotinylated Human B7-2 / CD86 Protein, Fc Tag, Avi Tag (Avitag?)|
|CD6-M5251||Mouse||Mouse B7-2 / CD86 Protein, Fc Tag|
|CD6-M52H0||Mouse||Mouse B7-2 / CD86 Protein|
B7-2 / CD86 Molecule Background
Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
- (1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
- (2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
- (3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.